What were the key takeaways from Amgen’s earnings call?

What were the key takeaways from Amgen's earnings call?

What is the revenue and EPS growth rate for Amgen year over year?

What is Amgen's latest dividend and current dividend yield?

Did Amgen beat or miss consensus estimates last quarter?

What does Amgen do and what are its main business segments?

What is Amgen's gross profit margin?

What factors drove the changes in Amgen's revenue and profit?

- **Revenue Growth**: Q2 revenue surpasses $10 billion, with 22 products achieving double-digit growth and six key drivers contributing 70% of sales.
- **Pipeline Momentum**: MariTide, olpasiran, and xaluritamig in late-stage trials; AI investments enhance R&D efficiency.
- **Financial Strength**: 48% non-GAAP margin, $3.5B free cash flow, and updated 2026 guidance for $38.2-$39.4B revenue.
- **Strategic Focus**: Expanding biosimilar portfolio, disciplined R&D spending, and 6% dividend increase.
- **Market Leadership**: Repatha grows 37% YoY, IMDELLTRA 115% YoY, and biosimilars 29% YoY, driven by clinical differentiation and execution excellence.

**【CEO Summary Section】**
- **Strong Q2 Performance**: Total revenue exceeded $10 billion, with 22 products achieving double-digit sales growth and 17 products annualizing above $1 billion. The six key growth drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, biosimilars) contributed 70% of sales, growing 26% YoY.
- **Pipeline and AI Investment**: $420 million invested in R&D, advancing MariTide, olpasiran, and xaluritamig. AI initiatives enhance drug discovery and manufacturing efficiency.
- **Long-Term Growth**: Confident in delivering durable growth through 2030, driven by first-in-class/best-in-class medicines and disciplined execution.

**【CFO Financial Commentary】**
- **Financial Highlights**: Non-GAAP operating margin of 48%, free cash flow of $3.5 billion, and capital expenditures of $500 million for manufacturing expansion.
- **Updated Guidance**: 2026 revenue forecast raised to $38.2-$39.4 billion, non-GAAP EPS to $22.30-$23.50. R&D expenses expected to grow high single digits YoY.
- **Shareholder Returns**: Dividend increased 6% to $2.52 per share, with $3 billion allocated for share repurchases.

**【Q&A Highlights】**
- **Lp(a) Strategy**: Olpasiran phase III trial (OCEAN(a)) targets high-risk patients, with 95% Lp(a) reduction. Differentiated endpoint focus on cardiovascular events vs. competitors.
- **Business Development**: Focused on early-stage assets in cardiometabolic, rare disease, and oncology, complementing internal pipeline.
- **Repatha Market Position**: Maintains leadership with unrivaled clinical evidence, 37% YoY growth, and 50% new-to-brand prescriptions YoY.
- **IMDELLTRA Monitoring**: Reducing monitoring requirements to 1-2 hours post-infusion, supporting broader adoption in frontline settings.
- **Otezla Impact**: Volumes stable despite biosimilar competition, with focus on first-line use in psoriasis.


AMGN

AMGN

Amgen (AMGN) Financials Overview

AMGN Q2 2026 Earnings

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Income Statement

Trend

Breakdown

Balance Sheet

Trend

Breakdown

Cash Flow

Trend

Breakdown

Revenue Breakdown

By Business

By Region

Dividend

Payout Ratio

Dividend Yield

You can ask Aime